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Bronchial asthma is a costly disease: while the role of pharmaceutical strategies was
greatly emphasised in order to alleviate its economic burden, the aetiological approach to
asthma has received much less attention from this point of view. The impact of gastro-
oesophageal reflux (GER)-related asthma was assessed in comparison to atopic asthma in
262 matched patients, and the corresponding direct and indirect annual costs calculated.
All subjects were screened by means of a 95-item self-questionnaire. The overall resource
utilisation was calculated for the last 12 months. Drug-induced annual costs were h290.4
(interquartile range—iqr 32.8) in atopic and h438.4 (iqr 27.8) in GER-related asthma
(po0.001); expenditure for medical consultations and diagnostics were h166.1 (iqr 14.8)
vs. h71.6 (iqr 11.0) (po0.001), and h338.4 (20.0) vs. 186.9 (iqr 26.5) (po0.001),
respectively. Direct costs due to hospital admissions and indirect costs due to absenteeism
were also higher in GER-related asthmatics: 2.201.7790.0 vs. h567.1711.0 (po0.001),
and h748.7794.7 vs. h103.6733.9 (po0.001), respectively. The total annual cost per
patient was h1246.7 (iqr 1979.6) in atopic and h3967.1 (iqr 3751.5) in GER-related asthma,
po0.001. In conclusion, GER-induced asthma has a more relevant economic impact on
healthcare resources than atopic asthma. Although further studies are needed, present
data tend to demonstrate that when facing difficult asthma (GER-related asthma in this
case), the aetiological assessment of the disease plays a critical role in optimising the
approach to patients’ needs.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Bronchial asthma is a disease which places a high burden on
healthcare resources. Usually, the determination of the
economic impact of bronchial asthma is based on cost-of-
illness analyses, which are aimed at assessing the distribu-
tion of healthcare resources used to manage the disease.1–4
The role of the various therapeutic strategies has been
greatly emphasised in health economic evaluations, most
likely because pharmaceutical intervention is generally
supposed to represent a crucial opportunity of achieving a
good control of asthma5–11 and of alleviating the economic
burden of the disease.
In contrast, the role of the aetiological determinants of
the disease received much less attention from this point of
view, although it is well known that assessment of the
precise origin of asthma can become difficult in some
circumstances (i.e. when the atopic cause is excluded),
independently of the therapeutic approach.
Increasing attention has been paid to bronchial asthma
when related to the occurrence of acid gastro-oesophageal
reflux (GER), and the causative (or triggering) role of GER
was emphasised in the last decade, particularly in non-
atopic subjects.12–17 GER-related asthma represents a
peculiar form of bronchial asthma which falls in the domain
of both gastroenterologists and pneumologists. Although it is
characterised by specific digestive symptoms (such as acid
regurgitation and heartburns), the diagnostic profile and the
patho-physiological pattern of this kind of asthma are still
difficult to depict by pneumologists.17
For these reasons, GER-related asthma was included in
the list of ‘‘difficult asthma forms’’ since long ago, and it can
represent a challenging model for investigating the role of a
particular aetiologic feature of asthma in affecting the
disease’s economic impact. At present, to our knowledge,
no published data are available on the economic burden of
GER-related asthma.
The aim of the present study was to assess the cost of
GER-related asthma and to compare its economic impact
with that of atopic asthma of the same severity.Material and methods
A cohort study of 246 adult asthmatics naı¨ve to our
Department (172 females; mean age 47.0716.6 SD; 28
smokers of o10 packs/year; 41 ex-smokers; FEV1 increase
X12% baseline, following inhaled salbutamol 200mcg
documented during the 6 months preceding the study) was
carried out for 12 months after obtaining their informed
consent. The study was approved by the local Ethical
Committee during the November 11, 2004 session; protocol
n. 400/6).
One hundred and forty-two subjects were assessed as
asthmatics of atopic origin (positive prick test to a 12-
allergen panel of inhalant allergens; Lofarma; Italy, and
RAST; Immulite 2000; DPC Diagnostic Products; Los Angeles,
CA, USA). All these subjects did not complain of any
significant digestive symptom for years.
One hundred and twenty subjects were assessed as non-
atopic (negative prick test and RAST) asthmatics who also
complained of significant digestive symptoms (such as dailyoccurrence of acid regurgitations and heartburns, or at least
X2 times/week). In these cases the presence of asthma-
triggering pathological acid GER was confirmed by 24-h pH
monitoring (Digitrapper MKIII, Synectics Medical AB, Stock-
holm, Sweden) after patients’ informed written consent.
When recruited, all subjects performed a further spir-
ometrical test (according to CECA guidelines, by means of
SyncMaster 510s, Jaeger, Hoeckberg, Germany) to assess
their current asthma severity, which was graded according
to the GINA guidelines.18
All subjects were investigated by means of a 95-item self-
questionnaire. The questionnaire was compiled to investi-
gate all subjects in terms of their demographics, smoke
habit, clinical history (such as the type, time of onset and
duration of respiratory and/or digestive symptoms), diag-
nostic course before assessing the cause of asthma (and the
overall duration of the diagnostic procedures), and also in
terms of their pharmacological history (such as the drugs
taken regularly and/or when needed, their doses, and
treatment duration).
The protocol just consisted in collecting data concerning
the diagnostic procedures, the therapeutic approach, and
the trend to hospitalisation established in all patients before
the recruitment in the study, without any decisional role by
the authors of the present observational survey. Any possible
inconsistency with current guidelines for asthma manage-
ment should be regarded as uniquely mirroring the real-life
management of both atopic and GER-related asthma in
general practice.
The overall healthcare resource utilisation (such as
number of hospitalisations, medical visits, work days off,
and costs for diagnostic tests and drugs) was calculated in
each subject for the last 12 months. Before the study start-
up, the questionnaire was tested in a small sample of other
subjects (n ¼ 22) during a 2-month pilot study to assess the
respondents’ comprehension of the items.
Pharmacoeconomic assessment
The present study was a cohort incremental study. Costs due
to drugs consumption were calculated according to the
prices published by the Informatore Farmaceutico ED, OEMF,
Milano, 2004.19
Expenditures due to visits to physicians were calculated
on the basis of the fares reported in the DM 22.07.1996,
Gazzetta Ufficiale n1 216, 14.09.1996.20
Costs due to hospitalisation were calculated on the basis
of the DM 14.12.1994 and DM 30.06.1997, suppl. Gazzetta
Ufficiale n1 209, 08.09.1997.21
Costs due to work loss were calculated for individuals
currently employed, according to the indications by the
Bank of Italy, 2002.22
Statistics
The Wilcoxon rank-sum test was used to test the hypothesis
that the distribution of a quantitative variable (costs, age,
etc.) is the same in the two groups of asthma subjects. The
random association between a categorical variable (sex,
smoke, etc.) and asthma aetiology was tested by Fisher’s
exact test; po0.05 was accepted as the minimum level of
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analytical and total (mean and median) annual costs were
estimated by classical regression and quantile regression
models for each type of cost: dependent variable was the
logarithm of the cost and the independent variables were
sex, age, basal FEV1, respiratory signs (age of onset and
duration) and the dichotomous variable atopic/GER-related
asthma. By this technique we evaluated the statistical
significance of the difference of the costs between the two
groups (Atopic vs. GER-related asthma) taking jointly into
account the effects of all the explanatory variables of the
two groups.
Due to the high skewness of the distribution of costs,
medians and interquartile ranges were used to describe
these variables in the two subgroups of subjects. If the
median value of a certain category of costs equals 0, the
corresponding arithmetic mean value is reported in order to
clarify the dimension of that cost.Results
The demographic and basal lung function characteristics of
the two samples of subjects are reported in Table 1.
Subjects in both subgroups were well matched in terms of
asthma severity (Table 1). Atopic asthma was slightly more
frequent in mild cases, while GER-related asthma was more
represented in severe asthmatics.
At the recruitment stage, mean FEV1 values were 84.9%
pred.719.3 SD in atopic and 80.8% pred.718.4 SD in GER-
related asthmatics, respectively (p ¼ ns). Females made upTable 1 Demographic and basal lung function characteristics o
Atopic asthma
Total (n) 142 (54.2%)
Gender: females (n) 72 (50.7%)
Age (years) 42.7715.6
Smokers (n) 22 (15.7%)
Basal FEV1 (l) 84.9719.3
Severity of illness
Mild 94 (66.2%)
Moderate 28 (19.7%)
Severe 20 (14.1%)
Respiratory signs
Age of onset (y) 28.2717.4
Duration (y) 14.5711.7
Digestive signs
Age of onset (y) —
Duration (y) —
Clinical tests (n) 7.176.9
Visits to GP’s office (n) 5.572.7
Absenteeism (days) 6.774.1
Hospitalisation
Rate (n) 49 (34.5%)
Duration (days) 17.8734.5
Drug load (n) 1.770.9
n, %, mean7SD; y, years.
Fisher’s exact test, Wilcoxon rank-sum test everywhere else.50.7% of atopic asthmatics, but were the great majority
(83.3%) of GER-related asthma subjects, with the mean age
of this group being significantly higher than that of atopic
subjects (52.0 years716.2 SD and 42.7 years715.6,
respectively, po0.001).
In atopic asthmatics (i.e. the younger group of subjects),
respiratory symptoms (i.e. coughing, wheezing, chest
tightness, shortness of breath) have an earlier onset (28.2
years717.4 SD vs. 44.5 years717.4 SD, po0.001) and a
longer mean duration than in GER-related asthmatics (14.5
years711.7 SD vs. 7.5 years710.7 SD, respectively, po
0.001).
GER-related asthmatics reported a long history of
digestive symptoms (i.e. frequent or daily acid regurgita-
tion, heartburns, belching) over a long period (mean
duration 15.4 years711.0 SD), which was twice as long as
that of respiratory symptoms (mean duration 7.5
years710.7 SD) in the same subject sample (po0.001).
The corresponding distributions of both of these mean
values are reported in Table 1.
Moreover, in GER-related asthmatics, the onset of
digestive symptoms (mean value ¼ 36.6 years714.8 SD)
systematically preceded that of respiratory symptoms
(mean value ¼ 44.5 years717.4 SD, po0.05; Table 1).
In general, the process for assessing the patients’ asthma
profile proved much more complicated in GER-related than
in atopic asthma subjects. In particular, the number of
clinical tests performed was significantly higher in GER-
related asthma patients (12.0710.4 SD vs. 7.677.0 SD,
respectively; po0.001). The mean number of visits to GPs
made in the same period was equivalent in both groups off subjects
GER-related asthma p value
120 (45.8%)
100 (83.3%) o0.001
52.0716.2 o0.001
12 (10.0%) 0.199
80.8718.4 0.060
72 (60.0%) 0.403
32 (26.7%)
16 (13.3%)
44.5717.4 o0.001
7.5710.7 o0.001
36.6714.8
15.4711.0
12.0710.4 o0.001
12.877.9 o0.001
26.9721.0 o0.001
112 (93.3%) o0.001
11.3710.0 0.829
3.671.6 o0.001
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Figure 1 Absenteeism in the total sample of subjects, in atopic, and in GER-related asthmatics.
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Figure 2 The therapeutic load and the frequency distribution
of the number of drugs taken by atopic and GER-related
asthmatics.
Table 2 Therapeutic approach and the ‘‘top eight’’
drugs for treatment of atopic and GER-related asthma.
%
Atopic asthma
LABA+ICS 44.1
SABA 19.5
Systemic steroids 9.1
Anti-H1/anti-LTs 7.8
Theophylline 7.3
Anti-tussive/mucoactive 4.8
Anxiolytic 3.3
Digestive 2.6
Prokinetic 1.9
PPI/anti-H2 0.7
GER-related asthma
Digestive 22.7
Prokinetic 16.1
Anti-H2/PPI 6.6
Systemic steroids 15.8
SABA 18.2
Anxiolytic 9.9
anti-tussive/mucoactive 9.1
ICS 7.4
Theophylline 7.0
LABA+ICS 4.5
SABA: short-acting b2 adrenergics; LABA: long-acting b2
adrenergics; ICS: inhaled corticosteroids; anti-H1: histamine
receptor 1 antagonists; anti-LTs: leukotriene receptor an-
tagonists; anti-H2: histamine receptor 2 antagonists; PPI:
proton pump inhibitors.
Cost analysis of GER-induced asthma 1817subjects: 5.572.7 SD in atopic and 12.877.9 SD in GER-
related asthmatics (p ¼ 0.001). Concerning absenteeism
from work, the mean number of days off registered for
GER-related asthmatics was significantly higher than that in
atopic asthmatics: mean value ¼ 26.9 days721.0 SD and
6.07 days74.1 SD, respectively (po0.001). The correspond-
ing distributions of values are reported in Table 1 and Fig. 1.
While the mean duration of hospital stay was similar in
the two subgroups of patients (both median value ¼ 7), the
hospitalisation rate proved quite different (93.3% vs. 34.5%,
po0.001).
The therapeutic approach was different in the two groups
of subjects. When considering the frequency distribution of
the number of drugs taken by patients, it is clear that GER-
related asthmatics usually had a higher therapeutic load
(Fig. 2). In particular, only 31.8% of atopic subjects and 3.3%
of GER-related asthmatics did not take a drug regularly, with
the large majority of patients in the latter group being
treated with more than two drugs concomitantly (Fig. 2).
The eight prevailing drugs for both groups (i.e. the ‘‘top
eight’’) are reported analytically in Table 2. While long-
acting b2-adrenergics (LABA) and inhaled steroids (ICS) were
the most frequently used therapeutic options (44.1%) inatopic asthmatics, digestive drugs (such as PPI, H2 antago-
nists, pro-kinetics) were the most frequently used (22.7%) in
GER-related asthmatics, together with anxiolytic drugs
(9.9%). The use of short-acting b2 adrenergics (SABA) was
quite similar in both groups (19.5% vs. 18.2%, respectively),
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Table 3 Analytical and total median annual costs per patient (in Euro) calculated in atopic and GER-related asthma subjects
(interquartile range (iqr), ratio of cost on total annual expenditure (%) and p-value of rank sum test in the two groups).
Atopic asthma GER-related asthma p-value
Median iqr % Median iqr %
Drug-induced 423.4 (604.4) 23.3 496.5 (860.1) 11.1 0.004
Medical visits 124.0 (82.6) 5.7 227.3 (247.9) 4.2 o0.001
Diagnostic tests 235.6 (194.8) 15.0 392.8 (336.6) 8.5 o0.001
Hospitalisation 567.1 (711.0) 45.5 2201.0 (790.0) 55.5 o0.001
Day hospital 24.7 (712.6) 2.0 43.6 (711.1) 1.1 o0.001
Absenteeism 103.6 (733.9) 8.3 748.7 (794.7) 18.9 o0.001
Total cost 1246.7 (1979.6) 100.0 3967.1 (3751.5) 100.0 o0.001
Mean7SD because median cost ¼ 0.
Median total cost calculated as the median of all costs distribution: for this reason, its value does not correspond to the simple sum
of different median costs reported.
R.W. Dal Negro et al.1818as well as that of theophylline (7.3% and 7.0%, respectively).
The use of systemic steroids was much higher in GER-related
asthmatics (15.8% vs. 9.1%). The consumption of other
symptomatic drugs (such as anti-tussive and mucoactive
drugs) was also higher in GER-related asthma subjects (9.1%
vs. 4.8%).
The median annual costs per patient calculated in the two
groups of subjects are reported analytically in Table 3,
together with median and interquartile range values. The
median overall drug-induced annual cost per patient was
h423.4 (iqr 604.4) in atopic and h496.5 (iqr 860.1) in GER-
related asthma subjects (p ¼ 0.04). Per-patient costs
induced by medical consultations (visits to GPs and lung
physicians) and those due to diagnostic procedures were
higher in GER-related asthmatics: h227.2 (iqr 247.9) vs.
h124.0 (iqr 82.6) (po0.001) and h392.8 (iqr 336.6) vs. 235.6
(iqr 194.8) (po0.001), respectively. Per-patient direct costs
due to hospital admissions were also higher in GER-related
asthma subjects: 2201.7790.0 SD vs. h567.1 711.0 SD
(po0.001). In particular, per-patient costs due to day-
hospital activities were h43.6711.1 SD and h24.7712.6 SD
(po0.001). Annual indirect costs due to days off work were
also higher in these subjects: h748.7794.7 SD vs.
h103.6733.9 SD (po0.001).
When compared to the corresponding total annual
expenditure, drugs accounted for 23.3% of total costs in
atopic and only 11.1% in GER-related asthma. The percent
economic impact of hospital admissions was 45.5% in atopic
and 55.5% in GER-related asthmatics, with absenteeism
being 8.3% and 18.9%, respectively.Discussion
Bronchial asthma is a costly disease which involves a high
resource utilisation. The economic impact of bronchial
asthma consists of direct medical expenditures (i.e.
payments for ambulatory care visits; hospital out-patient
services; hospital in-patient stays; visits to the emergency
department; prescribed medicines and diagnostic tests) andindirect medical costs (i.e. missed work; restricted activ-
ities; loss of work opportunities).1–4
In addition, the most recent pharmaco-economic studies
tend to emphasise that asthma is still receiving increasing
attention,5–8 and optimisation of the major outcomes is
usually achieved by comparing the efficacy and the
effectiveness of different therapeutic strategies, with good
pharmacological control of asthma being the primary goal in
these studies.9,10 The best choice of current pharmaceutical
options is generally regarded as the major opportunity to
achieve the best asthma control, simply reflecting the
actual value for money, even though the adequate diagnosis
and classification of asthma is a crucial point.11
Nevertheless, health economic studies have not examined
the different underlying aetiologic determinants of bron-
chial asthma, even though it has long been known that when
the atopic origin of bronchial asthma is excluded, assess-
ment of the precise origin of the disease can be very
difficult, and the appropriate diagnosis can frequently take
long time independently of the therapeutic strategies
adopted. Achieving good value for money is mainly affected
by the low specificity and long duration of the diagnostic
procedures in these cases, rather than by the therapeutic
approach to the disease, unless aetiologically oriented. In
other words, the ‘‘diagnosis effect’’ should also play a
crucial role in the overall cost-of-illness analysis of asthma.
The evidence concerning the triggering and/or the
causative role of GER in asthma (particularly in non-atopic
subjects) has been strongly emphasised in recent years also
in clinical studies.12–17 At present, GER-related asthma still
represents a type of asthma where the onset, or the
persistence, of specific digestive symptoms is only infre-
quently supported by corresponding significant changes in
lung parameters (such as volume, flow, conventional
bronchial hyper-responsiveness),23–26 and the diagnostic
pattern of asthma can then be difficult depicted in a short
time.
All these findings contributed to the inclusion of GER-
related asthma in the group of ‘‘difficult asthma’’. Although
it has never been considered from this point of view, the
clinical difficulties in assessing the true origin of this type of
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economic costs, which is mainly related to its delayed
aetiologic diagnosis and consequently to its inappropriate
clinical management.
To our knowledge, no controlled investigation has been
published to date, and the present study can be regarded as
the first pivotal study on this specific topic.
In general terms, data from the present study tend to
indicate that GER-related asthma is much more costly than
atopic asthma, despite the fact that the respiratory
symptoms have a shorter mean duration (i.e. their onset
occurs in later ages), and mainly affects subjects who report
notable digestive symptoms that started long before. This
particular information confirms previous studies which
proved that asthma due to GER mainly occurs in older
people than atopic asthma, and that females are more
affected.27
The difficulty in defining the pathogenic relationship
between the subject’s complaint of both digestive and
respiratory symptoms is likely reflected by the large number
of clinical and instrumental tests required to clarify the
cause of asthma in these cases. All these diagnostic
procedures significantly affect total healthcare costs, both
direct and indirect costs.
The higher level of absenteeism and the more frequent
hospitalisations documented in this group of subjects can be
likely explained by the persisting diagnostic uncertainty.
Unfortunately, a longer delay in the aetiologic diagnosis of
asthma is frequent when facing this kind of clinical
problems, being the uncertainty in the diagnostic process
also confirmed by the growing trend of heavier therapeutic
loads systematically found in GER-related asthmatics (i.e.
an average of three different drugs in 50% of subjects).
Furthermore, the therapeutic approach to GER-related
asthma proves frequently inadequate, being teophylline
(such as a pro-refluxant drug), oral steroids and ansiolytics
too widely used in these cases. These patients most likely
prove to be unresponsive to conventional first-line asthma
treatments, and further therapeutic options are continu-
ously added in the attempt to achieve a better control of the
disease.
Contrary to the clear therapeutic options generally
registered in atopic asthma (which were in pretty good
agreement with the international guidelines), the thera-
peutic approach to GER-related asthma usually reflects a
persisting symptomatic approach to this digestive–respira-
tory disease, particularly intriguing.
In the present study, the mean absolute cost of drug
consumption was higher than in previous healthcare
investigations on asthma.3,4 However, in the present study,
mild, moderate and severe asthma were assessed according
to the ‘‘during treatment’’ GINA classification; in these
cases, the intrinsic severity of the disease18 was more
relevant and the mean patient drug requirement higher.
Because GER-related asthma frequently affects individual
who are still active and productive, hospital in-patient stay,
hospital out-patient services and absenteeism from produc-
tive activities actually represent the major categories of
expenditure (66.1% mean total costs). It should also be
emphasised that the long time required for diagnostic
procedures and diagnostic conclusions can contribute
towards increasing the direct and indirect costs. In ouropinion, the difference in illness-associated costs between
GER-related and atopic asthma proved too high to be
suggested as solely dependent of the slight difference in
distribution of asthma severity as observed in the two
groups.
In conclusion, GER-induced asthma seems to cause a much
higher economic impact than atopic asthma. Although
further studies are needed, data from the present pivotal
study tends to suggest that when facing difficult asthma,
GER-related asthma in this case, stringent attention to the
precise aetiological definition of the disease can play a
critical role (i.e. a sort of ‘‘diagnosis effect’’) in limiting
healthcare expenditures and in optimising the approach to
patients’ needs.References
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